Related Experiment Video
Updated: Aug 5, 2026
10:39
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Uterine sarcoma associated with tamoxifen use: case report
M Martin-Loeches1, J Rius, R M Orti
1Department of Gynaecology, Marina Alta University Hospital, Alicante, Spain.
European Journal of Gynaecological Oncology
|April 19, 2003
Summary
A rare müllerian adenosarcoma with sarcomatous overgrowth was diagnosed in a postmenopausal woman after tamoxifen treatment for breast cancer. This case highlights a potential association between tamoxifen and mesenchymal neoplasms.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Pathology
Background:
- Tamoxifen is a widely used adjuvant endocrine therapy for breast carcinoma.
- Müllerian adenosarcoma is a rare uterine malignancy, often with a low-grade sarcomatous component.
- Postmenopausal women are at increased risk for gynecologic neoplasms.
Observation:
- A 66-year-old postmenopausal female patient with a history of breast carcinoma treated with adjuvant tamoxifen presented asymptomatically.
- Pelvic sonography incidentally detected a uterine neoplasm.
- Diagnosis was confirmed via histological examination of curettage and subsequent hysterectomy specimens.
Findings:
- The patient was diagnosed with müllerian adenosarcoma exhibiting sarcomatous overgrowth.
- Histopathological analysis revealed features consistent with this rare müllerian tumor.
- The tumor was detected incidentally, with the patient remaining asymptomatic.
Implications:
- This case suggests a potential association between adjuvant tamoxifen therapy and the development of müllerian adenosarcoma with sarcomatous overgrowth.
- Further research is warranted to elucidate the potential link between tamoxifen and mesenchymal uterine neoplasms.
- Increased vigilance and surveillance may be considered in postmenopausal women with a history of tamoxifen use presenting with gynecologic abnormalities.
